Form 8-K/A
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 3)
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 5, 2011
MIMEDX GROUP, INC.
(Exact name of registrant as specified in its charter)
         
Florida   000-52491   26-2792552
         
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer Identification No.)
     
811 Livingston Court, Suite B
Marietta, GA
   
30067
     
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (678) 384-6720
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 

Item 2.01   Completion of Acquisition or Disposition of Assets
As previously disclosed in our Current Report on Form 8-K dated January 6, 2011 filed with the Securities and Exchange Commission on January 5, 2011, MiMedx Group, Inc., (“MiMedx” or the “Company”) completed its acquisition of Surgical Biologics, LLC, formerly owned by Membrane Products Holdings, LLC and OnRamp Capital Investments, LLC, headquartered in Kennesaw, Georgia. Surgical Biologics will operate as a wholly owned subsidiary of the Company.
This Current Report on Form 8-K/A provides pro forma financial information required under Item 9.01(b). The aforementioned pro forma information was not included in the Current Report on Form 8-K filed on January 6, 2011. This pro forma information uses the audited consolidated financial statements from the Company’s Annual Report on form 10-K, filed on March 31, 2011
Item 9.01   Financial Statements and Exhibits
(a)   Financial Statements of Business Acquired.
The unaudited pro forma combined financial statements, as of the year ended December 31, 2010, including the notes to such unaudited pro forma financial statements, are filed as Exhibit 99.2 herewith.
     
Exhibit Number   Description of Exhibit
99.2
  The unaudited pro forma combined financial statements as of and for the year ended December 31, 2010 for MiMedx Group, Inc. and Surgical Biologics, LLC, including the notes to such unaudited pro forma financial statements.

 

2


 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
MIMEDX GROUP, INC.
 
 
Dated: April 1, 2011    By:   /s/: Michael J. Senken    
    Michael J. Senken, Chief Financial Officer   
       

 

3


 

         
EXHIBIT INDEX
     
Exhibit    
Number   Description
Exhibit 99.2
  The unaudited pro forma combined financial statements as of and for the year ended December 31, 2010 for MiMedx Group, Inc. and Surgical Biologics, LLC, including the notes to such unaudited pro forma financial statements.

 

4

Exhibit 99.2
EXHIBIT 99.2
UNAUDITED PRO FORMA FINANCIAL INFORMATION
On January 5, 2011, MiMedx Group, Inc. (“MiMedx” or the “Company”) acquired all of the outstanding equity interests in Surgical Biologics, LLC (“SB”), formerly owned by Membrane Products Holdings, LLC and OnRamp Capital Investments, LLC. Surgical Biologics primary business is in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes. The purchase price was approximately $8,838,000, which was comprised of 5,200,000 shares of MiMedx common stock valued at $1.35 per share, plus $500,000 in cash (subject to adjustment in Surgical Biologics’ working capital from the agreed amount, debt in excess of the agreed amount and SB’s transaction costs); plus a $1,250,000 Convertible Secured Promissory Note. In addition, the Merger Agreement provides for the payment of additional contingent consideration equal to 60% of the excess of MiMedx’s gross revenue in calendar year 2011 from sales of all SB’s products over SB’s gross revenue from sales of such products in calendar year 2010; and contingent consideration equal to 30% of the excess of MiMedx’s gross revenue in calendar year 2012 from sales of all SB’s products over SB’s gross revenue from sales of such products in calendar year 2011. The contingent consideration is preliminarily valued at $7,400,000.
The following unaudited pro forma combined financial statements reflect the acquisition of 100% of the membership interests of Surgical Biologics using the purchase method of accounting. The acquisition has been accounted for in conformity with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 805, Business Combinations (“ASC 805”). The pro forma adjustments are based upon available information and assumptions that we believe are reasonable. The pro forma adjustments are preliminary and have been prepared to illustrate the estimated effect of the acquisition. Differences between these preliminary estimates and the final acquisition accounting will occur and these differences could have a material impact on the accompanying unaudited pro forma combined financial statements and the combined companies’ future results of operations and financial position. The unaudited pro forma combined financial statements do not purport to be indicative of the operating results or financial position that would have been achieved had the acquisition taken place on the date indicated or the results that may be obtained in the future.
The unaudited pro forma combined balance sheet as of December 31, 2010 is presented as if our acquisition of SB had occurred on December 31, 2010.
The unaudited pro forma combined consolidated statements of income for the year ended December 31, 2010 illustrate the effect of the SB acquisition as if it had occurred on January 1, 2010. The unaudited pro forma combined consolidated statement of operations combines the MiMedx and SB unaudited statements of income for the year ended December 31, 2010. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (i) directly attributable to the acquisition (ii) factually supportable, and (iii) with respect to the statements of income, expected to have a continuing impact on the combined results of the companies. These unaudited pro forma condensed combined financial statements are prepared by management for informational purposes only in accordance with Article 11 of Securities and Exchange Commission Regulation S-X and are not necessarily indicative of future results or of actual results that would have been achieved had the acquisition been consummated as of the dates presented, and should not be taken as representative of future consolidated operating results of MiMedx. The unaudited pro forma combined financial statements do not reflect any operating efficiencies and/or cost savings that we may achieve, or any additional expenses or costs of integration that we may incur, with respect to the combined companies as such adjustments are not factually supportable at this point in time. The assumptions used to prepare the pro forma financial information are contained in the notes to the unaudited pro forma combined financial statements, and such assumptions should be reviewed in their entirety.
The unaudited pro forma combined financial statements have been developed from, and should be read in conjunction with the historical audited consolidated financial statements for the year ended December 31, 2010 and notes thereto of MiMedx contained in its Annual Report on Form 10-K which was filed on March 31, 2011.

 

1


 

MIMEDX GROUP, INC. AND SUBSIDIARIES
Unaudited Pro Forma Combined Balance Sheet
December 31, 2010
                                 
    Historical     Historical              
    MiMedx     Surgical Biologics              
    December 31,     December 31,     ProForma     ProForma  
    2010     2010     Adjustments     Combined  
ASSETS
                               
 
                               
Current assets:
                               
Cash and cash equivalents
  $ 1,340,922     $ 33,583     $ (500,000 )(A)   $ 874,505  
Accounts receivable, net of allowance
    162,376       181,087               343,463  
License receivable
          340,000               340,000  
Inventory, net
    111,554       347,106               458,660  
Prepaid expenses and other current assets
    90,946       2,738               93,684  
 
                       
 
                               
Total current assets
    1,705,798       904,514       (500,000 )     2,110,312  
 
                               
Property and equipment, net
    756,956       72,866               829,822  
Goodwill
    857,597               7,530,146 (B)     8,387,743  
Intangible assets, net of accumulated amortization
    3,929,394               8,145,000 (C)     12,074,394  
Deposits and other long term assets
    102,500       16,582               119,082  
 
                       
 
                               
Total assets
  $ 7,352,245     $ 993,962     $ 15,175,146     $ 23,521,353  
 
                       
 
                               
LIABILITIES AND MEMBERS’ EQUITY
                               
 
                               
Current liabilities:
                               
Accounts payable and accrued expenses
  $ 848,285     $ 196,101     $ 202,024 (D)   $ 1,246,410  
Deferred rent and customer deposits
          36,533               36,533  
Current portion of debt
    403,432       62,590               466,022  
 
                       
Total current liabilities
    1,251,717       295,224       202,024       1,748,965  
 
                               
Long Term Liabilities
                       
Deferred rent — noncurrent
          16,197               16,197  
Debt, net of current portion
          21,187       1,250,000 (E)     1,271,187  
Line of Credit
            99,000               99,000  
 
                       
 
                               
Total liabilities
    1,251,717       431,608       1,452,024       3,135,349  
 
                       
 
                               
 
                               
Stockholders’ equity:
                               
 
                               
Preferred stock; $.001 par value; 5,000,000 shares suthorized and 0 shares issued and outstanding
                         
Common stock; $.001 par value; 100,000,000 shares authorized; 64,331,910 and 50,002,887 shares issued and outstanding, respectively
    64,382             10,731 (F)     75,113  
Additional paid-in capital
    57,888,506             14,476,769 (F)     72,365,275  
Treasury Stock
    (25,000 )                   (25,000 )
Retained Earnings (Accumulated deficit)
    (51,827,360 )     562,354       (562,354 )(G)     (52,029,384 )
 
                    (202,024 )(D)        
 
                       
Total stockholders’ equity
    6,100,528       562,354       13,723,122       20,386,004  
 
                               
Total liabilities and members’ equity
  $ 7,352,245     $ 993,962     $ 15,175,146     $ 23,521,353  
 
                       

 

2


 

MIMEDX GROUP, INC. AND SUBSIDIARIES
Unaudited Combined Statement of Operations
For The Year Ended December 31, 2010
                                 
    Historical     Historical              
    MiMedx     Surgical Biologics              
    For the year ended     For the year ended     Pro Forma     Pro Forma  
    December 31, 2010     December 31, 2010     Adjustments     Combined  
REVENUES:
                               
Net Sales
  $ 544,155     $ 1,707,213     $     $ 2,251,368  
Grant Revenue
    244,719                       244,719  
Licensing revenue
            500,000               500,000  
 
                       
Total revenue
    788,874       2,207,213               2,996,087  
 
                               
OPERATING COSTS AND EXPENSES:
                               
Cost of products sold
    1,720,063       603,381               2,323,444  
Research and development expenses
    2,753,331       154,542               2,907,873  
Selling, general and administrative expenses
    6,848,135       1,256,780       581,786 (I)     8,686,701  
 
                       
INCOME/LOSS) FROM OPERATIONS
    (10,532,655 )     192,510       (581,786 )     (10,921,931 )
 
                               
OTHER INCOME (EXPENSE), net
                               
Financing expense associated with warrants issued in connection with convertible promissory note
    (287,449 )                     (287,449 )
Interest (expense) income, net
    (599,649 )     (10,523 )     (50,000 )(H)     (660,172 )
 
                       
PROFIT/(LOSS) BEFORE INCOME TAXES
    (11,419,753 )     181,987       (631,786 )     (11,869,552 )
 
                               
Income Taxes
                         
 
                               
NET INCOME (LOSS)
  $ (11,419,753 )   $ 181,987     $ (631,786 )   $ (11,869,552 )
 
                       
 
                               
Net loss per common share
                               
Basic and diluted
  $ (0.19 )                   $ (0.17 )
 
                               
Shares used in computing net loss per common share
                               
Basic and diluted
    59,138,357               10,706,481 (J)     69,844,838  
 
                               

 

3


 

MIMEDX GROUP, INC.
Notes to Unaudited Pro Forma Combined Financial Statements
1.   Background and Basis of Pro Forma Presentation
 
    On January 5, 2011, MiMedx Group, Inc. (“MiMedx” or the “Company”) acquired the outstanding equity interests in Surgical Biologics, LLC, (“SB”) formerly owned by Membrane Products Holdings, LLC and OnRamp Capital Investments, LLC. Surgical Biologics primary business is in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.
 
    The unaudited pro forma combined financial information was prepared based on the historical financial statements of MiMedx and SB.
 
    Our acquisition has been accounted for in conformity with ASC 805 and uses the fair value concepts defined in Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC 820-10”). ASC 805 requires, among other things, that most assets acquired and liabilities assumed in an acquisition be recognized at their fair values as of the acquisition date and requires that fair value be measured based on the principles in ASC 820-10. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820-10 also requires that a fair value measurement reflect the assumptions market participants would use in pricing an asset or liability based on the best information available.
 
2.   Purchase Price Allocation
 
    The acquisition is accounted for using the acquisition method of accounting. The total estimated purchase price is comprised of the following:
         
Cash paid at closing
  $ 500,000  
Common Stock Issued
    7,087,500  
Convertible note payable
    1,250,000  
Estimated present value of additional contingent consideration
    7,400,000  
 
     
Total
  $ 16,237,500  
 
     

 

4


 

    The following table summarizes the preliminary allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of January 5, 2011 as if the acquisition had occurred on December 31, 2010.
         
Cash and cash equivalents
  $ 33,583  
Trade receivables
    181,087  
License receivables
    340,000  
Inventory
    347,106  
Prepaid expenses and other current assets
    2,738  
Property and equipment, net
    72,866  
Goodwill
    7,530,146  
Intangible Assets, net
    8,145,000  
Deposits and other long term assets
    16,582  
 
     
Total assets acquired
  $ 16,669,108  
 
       
Accounts Payable and accrued expenses
    196,101  
Deferred rent and customer deposits
    36,533  
Debt
    83,777  
Deferred rent
    16,197  
Line of Credit
    99,000  
 
     
Net Assets acquired
  $ 16,237,500  
3.   Pro Forma Financial Statement Adjustments
 
    The following pro forma adjustments are included in the Company’s unaudited pro forma combined financial statements:
 
     
(A)   Cash due upon closing
 
(B)   To record preliminary estimate of goodwill for our acquisition of Surgical Biologics
 
(C)   To record the preliminary estimate of the fair value of intangible assets for our acquisition of Surgical Biologics. The amortizable intangible assets acquired are comprised of the following: approximately $3,100,000 of customer relationships, $245,000 of supplier relationships, and $4,800,000 of patents & knowhow. All items are amortized over a 14 year period
 
(D)   To reflect impact of non-recurring acquisition related transaction costs
 
(E)   To record 4% Convertible Note Payable due in eighteen months
 
(F)   To record 5,250,000 shares and 5,481,481 contingent shares of MiMedx common stock issued in connection with the acquisition of Surgical Biologics LLC valued at $1.35 per share, the closing price of MiMedx stock on the closing date
 
(G)   To eliminate Surgical Biologics Member’s Equity
 
(H)   To record interest expense on Convertible Note Payable
 
(I)   Adjustment to record amortization expense related to intangible assets acquired
 
(J)   To reflect 5,250,000 shares of MiMedx common stock issued at closing and 5,481,481 contingent shares of MiMedx common stock to be issued based upon achievement of certain revenue goals

 

5